Radiopharmaceutical Therapy (RPT) is an emerging modality with significant potential to impact future oncological management across many disease settings.
Theranostics, a treatment paradigm pairing diagnostic molecular imaging with radiopharmaceutical therapy (RPT), is resurgent, mainly driven by the FDA approvals of 177Lu-dotatate for neuroendocrine tumors and 177Lu-PSMA-617 for prostate cancer.
Radiation dosimetry plays a critical role in the development and application of radiotherapeutic pharmaceuticals, ensuring both efficacy and safety in treatment.
Miscellaneous and Future Applications of Radiopharmaceutical Therapy – How To Become an Authorized User, Meta-iodobenzylguanidine, Rhenium Skin Cancer Therapy, Radiosynoviorthesis, Alpha Emitters, Other